genetically engineered lymphocyte therapy

BIOLOGICAL4 trials

Sponsors

Fred Hutchinson Cancer Center, City of Hope Medical Center, Chinese PLA General Hospital, M.D. Anderson Cancer Center

Conditions

Adult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHematopoietic/Lymphoid CancerNodal Marginal Zone B-cell LymphomaProlymphocytic LeukemiaRecurrent Adult Diffuse Large Cell Lymphoma

Phase 1

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

CompletedNCT00621452

Fred Hutchinson Cancer CenterB-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma +8

Start: 2007-08-31Target: 12Updated: 2014-08-06

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Active, not recruitingNCT01318317

City of Hope Medical CenterRecurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma +2

Start: 2011-09-19End: 2026-02-26Updated: 2025-04-25

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Chinese PLA General HospitalAdult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia +20

Start: 2013-01-31End: 2018-10-31Target: 50Updated: 2015-09-29

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

CompletedNCT04074746

M.D. Anderson Cancer CenterRecurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma +7

Start: 2020-07-18End: 2025-09-22Updated: 2025-09-30

Related Papers

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

2025-04-0420 citations

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Blood2024-11-053 citations

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Blood2023-11-0219 citations

AFM13 enhances the anti‐tumor activity of AB‐101 towards CD30+ tumors, conferring tumor growth control in vivo

Hematological Oncology2023-06-01

Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Blood2022-11-1523 citations

Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy

Blood2022-11-15

Abstract CT003: Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma

Cancer Research2022-06-1516 citations

Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies

Blood2021-11-051 citations

Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

Blood2016-04-27326 citations

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.

2016-03-11104 citations

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Blood2015-12-034 citations

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.

2014-10-16151 citations